| BCBS Oklahoma Medical Policies | Narsoplimab-wuug | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Onasemnogene abeparvovec-brve | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Oncology Medications | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Prostate Artery Embolization for Benign Prostatic Hyperplasia | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Remdesivir | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Tezepelumab-ekko | 2026-07-01 |
| BCBS Oklahoma Medical Policies | Ustekinumab and Associated Biosimilars | 2026-07-01 |
| BCBS Texas Medical Policies | Bioengineered Skin and Soft Tissue Substitutes | 2026-07-01 |
| BCBS Texas Medical Policies | Category III Current Procedural Terminology (CPT®) Codes | 2026-07-01 |
| BCBS Texas Medical Policies | Efgartigimod alfa-fcab or Efgartigimod alfa and hyaluronidase- | 2026-07-01 |